Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans

Dapagliflozin, a selective sodium–glucose co-transporter-2 inhibitor, and linagliptin, a competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed antidiabetic medications in general clinics. Since there are several merits to combining them in a fixed-dose combination product...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Jin-Woo Park, Jong-Min Kim, Ji Hyeon Noh, Kyoung-Ah Kim, Hyewon Chung, EunJi Kim, Minja Kang, Ji-Young Park
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2022-03-01
سلاسل:	Pharmaceutics
الموضوعات:	dapagliflozin linagliptin fixed-dose combination products bioequivalence
الوصول للمادة أونلاين:	https://www.mdpi.com/1999-4923/14/3/591
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!